IL-6 in inflammation, immunity, and disease.

@article{Tanaka2014IL6II,
  title={IL-6 in inflammation, immunity, and disease.},
  author={Toshio Tanaka and M. Narazaki and T. Kishimoto},
  journal={Cold Spring Harbor perspectives in biology},
  year={2014},
  volume={6 10},
  pages={
          a016295
        }
}
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity. For this reason, tocilizumab, a humanized anti-IL-6 receptor… Expand

Paper Mentions

Observational Clinical Trial
COVID -19, first reported in Wuhan, China, strikes the world hard as a pandemic by spreading up to 213 countries. Bangladesh is also facing its havoc with the death of 3000 among 229… Expand
ConditionsCytokine Storm, COVID-19
Regulation of IL-6 in Immunity and Diseases.
TLDR
Further elucidation of the factors and processes involved in IL-6 expression can be expected to facilitate to clarification of pathogenesis and to identification of novel target molecule(s) for specific diseases. Expand
Interleukin (IL-6) Immunotherapy.
TLDR
Lines of recent evidence strongly suggest IL-6 blockade can provide broader therapeutic strategy for various diseases included in acute systemic and chronic inflammatory diseases. Expand
Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish
TLDR
Off-label use and clinical trials strongly indicate that tocilizumab will be applicable for a wide variety of acute and chronic inflammatory diseases. Expand
Targeting Interleukin-6 in Ocular Inflammatory Diseases
TLDR
The basic biology of IL-6 and its pathological role in the development of immune-mediated conditions, particularly focusing on inflammatory eye diseases are discussed, and an overview of the on-going clinical trials with the new anti-IL-6 mAbs and their potential use in the clinical practice is provided. Expand
From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis
TLDR
The role of IL-6 in orchestrating innate and adaptive immune responses and its immunopathological relevance for chronic inflammatory diseases and cancer is described and an outlook on novel therapeutic strategies targeting IL- 6 signaling is provided. Expand
Targeting interleukin-6 in autoimmune uveitis.
TLDR
The basic biology of IL-6 and its pathological role in the development of immune-mediated conditions, particularly focusing on inflammatory eye diseases are discussed, and an overview of the on-going clinical trials with the new anti-IL-6 mAbs and their potential use in the clinical practice is provided. Expand
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.
TLDR
The recent findings and studies by others support a role for the indirect attenuation of B cell responses by Glatiramer acetate (GA) therapy and suggest that GA therapy temporarily permits homeostatic regulatory mechanisms to be reinstated. Expand
Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
TLDR
Initial data from the group suggest anti-IL-6R therapy is of value in desensitization and prevention and treatment of antibody-mediated rejection, and suggests that anti- IL-6/IL- 6R blockade could be effective in modifying T- and B-cell responses to allografts. Expand
Targeting Interleukin-6 Signaling in Clinic.
TLDR
The current state of IL-6-targeting approaches in the clinic is reviewed and how to apply the growing understanding of the immunobiology ofIL-6 to clinical decisions is discussed. Expand
Cytokines and their roles in pathological conditions
Cytokines mediate the innate immune response and if their actions sustained and/or dysregulated, pathological conditions resulted. Among cytokines, interleukins (ILs) which bind to specific receptorsExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 133 REFERENCES
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
TLDR
Clinical trials of tocilizumab, a humanized anti-IL-6 receptor antibody have verified its efficacy and tolerable safety for patients with rheumatoid arthritis, Castleman's disease and systemic juvenile idiopathic arthritis, resulting in approval of this innovative biologic for treatment of these diseases. Expand
Therapeutic targeting of the interleukin-6 receptor.
TLDR
In murine models of autoimmune diseases, anti- IL-6RAb induces Treg and inhibits Th17 and/or Th1 differentiation, indicating that anti-IL- 6RAb may be able to repair Th17/Treg imbalance in human diseases as well. Expand
Interleukin 6 Is Required for the Development of Collagen-induced Arthritis
TLDR
It is suggested that IL-6 receptor antagonists might be beneficial for the treatment of RA, accompanied by a reduced antibody response to type II collagen and the absence of inflammatory cells and tissue damage in knee joints. Expand
Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases
TLDR
Clinical trials to evaluate the efficacy and safety of tocilizumab for rheumatoid arthritis and other immune-mediated diseases are essential, and clarification of the cell source of IL-6 production and of the mechanisms through which dysregulated continuous IL- 6 synthesis is induced constitutes an important issue for future studies into the pathogenesis of diseases. Expand
Interleukin-6 in biology and medicine.
TLDR
Application of IL-6 is promising in cancer treatment as well as in treatment of radiation- or chemotherapy-induced myelosuppression and the cell biology of the intracellular events that link transduction to gene regulation is an important area, and work on these topics helps to understand such phenomena as multifunction of IL -6 and bidirectional effects of cell growth depending on the cell type. Expand
Biological and clinical aspects of interleukin 6.
TLDR
In this review, Toshio Hirano and colleagues discuss the possible involvement of IL-6 in a variety of diseases, the regulatory mechanism(s) of expression of the IL- 6 gene and the structure and function of theIL-6 receptor. Expand
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
TLDR
The findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to T NF blockade. Expand
Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system
TLDR
It is shown that IL-27 receptor–deficient mice chronically infected with Toxoplasma gondii developed severe neuroinflammation that was CD4+ T cell dependent and was associated with a prominent IL-17 response. Expand
Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.
TLDR
This study demonstrates for the first time that inhibition of IL-6 function by TCZ corrects the imbalance between Th17 cells and Treg cells in patients with RA. Expand
Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?
TLDR
Results of in vitro as well as in vivo studies using RA animal models indicate that IL-6 blockade could rectify the imbalance between Tregs and Th17 cells, although the exact mechanisms through which TCZ could have its beneficial effect on RA patients remain to be determined. Expand
...
1
2
3
4
5
...